Bristol Myers Squibb

News

Bayer pulls atrial fibrillation study for asundexian

Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation (AF), after an interim analysis concluded

News

BMS gets US approval for ROS1 lung cancer drug Augtyro

Bristol-Myers Squibb has secured FDA approval for Augtyro, a lung cancer therapy it acquired as part of its $4.1 billion takeover of Turning Point Therapeutics last year t

News

BMS extends its position in ADCs with $180m Orum deal

Bristol-Myers Squibb has signed another deal to build its capabilities in antibody-drug conjugates for cancer, paying $100 million upfront to take control of an Orum Thera

News

Bayer doubles down on Factor XIa with new phase 3 trial

Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixe

News

ESMO: J&J’s Tagrisso challenge, and other highlights

With Europe’s premier cancer congress ESMO now finished, we close our coverage with a look at some other important new studies that generated a buzz at the show.

News

BMS buys Asian rights to key growth drug Camzyos

Bristol-Myers Squibb has decided it wants complete, worldwide control of cardiovascular drug mavacamten, tipped as a future blockbuster, so it has paid $350 million to sho

Bayer pulls atrial fibrillation study for asundexian

BMS gets US approval for ROS1 lung cancer drug Augtyro

BMS extends its position in ADCs with $180m Orum deal

Bayer doubles down on Factor XIa with new phase 3 trial

ESMO: J&J’s Tagrisso challenge, and other highlights

BMS buys Asian rights to key growth drug Camzyos

Protego's $130m for amyloidosis drug, and other financings

How to meet your physicians where they are online

Bristol Myers Squibb

Editor's Picks